Table 3.

Bioavailability of the three tablet strengths: Study 1 point estimates and 90% CIs

Study regimen description	Pharmacokinetic parametersa	Central valueb		Relative bioavailability
		Test	Reference	Point estimatec	90% CI
2 × 50 mg tablets versus 1 × 100 mg tablet	Cmax	0.522	0.557	0.937	0.852–1.031
	AUCt	5.83	6.56	0.889	0.808–0.979
	AUC∞	5.98	6.72	0.890	0.809–0.979
10 × 10 mg tablets versus 2 × 50 mg tablets	Cmax	0.515	0.522	0.986	0.896–1.085
	AUCt	5.78	5.83	0.991	0.900–1.090
	AUC∞	5.93	5.98	0.992	0.902–1.091
10 × 10 mg tablets versus 1 × 100 mg tablet	Cmax	0.515	0.557	0.924	0.840–1.017
	AUCt	5.78	6.56	0.881	0.800–0.969
	AUC∞	5.93	6.72	0.883	0.803–0.971

Note: All groups were conducted under moderate-fat conditions consisting of ≤ 700 Kcal with ≤ 20% of the total caloric intake from fat

AUC_∞ area under the plasma concentration–time curve from time zero to infinite time, AUC_t area under the plasma concentration–time curve from time zero to time of the last measurable concentration, CIs confidence intervals, C_max maximum observed plasma concentration

^aUnits for C_max and AUC are expressed as μg/mL and μg⋅h/mL, respectively

^bAnti-logarithm of the least squares means for logarithms

^cAnti-logarithm of the difference (test minus reference) of the least squares means of the logarithms